integrilin 75mg100ml solution for infusion vials
glaxosmithkline uk ltd - eptifibatide - solution for infusion - 750microgram/1ml
eptifibatide 75mg100ml solution for infusion vials
accord healthcare ltd - eptifibatide - solution for infusion - 750microgram/1ml
eptifibatide strides 0.75 mg/ml solution for infusion
strides arcolab international limited - eptifibatide - solution for infusion - 0.75 mg/ml
eptifibatide strides 0.75 mg/ml solution for infusion
generics (uk) limited - eptifibatide - solution for infusion - 0.75 mg/ml - platelet aggregation inhibitors excl. heparin
integrilin 0,75mg/ml solution for infusion
glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml
integrilin solution for infusion
glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml
normosang 25 mg/ml inf. sol. (conc.) i.v. amp.
recordati rare diseases s.a.r.l. - haem human 25 mg/ml - concentrate for solution for infusion - 25 mg/ml - haem human 25 mg/ml - other hem products
normosol-r and dextrose- dextrose, sodium chloride, sodium acetate anhydrous, sodium gluconate, potassium chloride, and magnesiu
hospira, inc. - dextrose, unspecified form (unii: iy9xdz35w2) (dextrose, unspecified form - unii:iy9xdz35w2), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium acetate anhydrous (unii: nvg71zz7p0) (sodium cation - unii:lyr4m0nh37), sodium gluconate (unii: r6q3791s76) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838) - dextrose 5 g in 100 ml - normosol-r and 5% dextrose injection is indicated for replacement of acute extracellular fluid volume losses in surgery, trauma, burns or shock. normosol-r and 5% dextrose also can be used as an adjunct to restore a decrease in circulatory volume in patients with moderate blood loss. the solution is not intended to supplant transfusion of whole blood or packed red cells in the presence of uncontrolled hemorrhage or severe reductions of red cell volume. none known.
normosol-r and dextrose- dextrose, sodium chloride, sodium acetate anhydrous, sodium gluconate, potassium chloride, and magnesiu
icu medical inc. - dextrose, unspecified form (unii: iy9xdz35w2) (dextrose, unspecified form - unii:iy9xdz35w2), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium acetate anhydrous (unii: nvg71zz7p0) (sodium cation - unii:lyr4m0nh37), sodium gluconate (unii: r6q3791s76) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838) - normosol-r and 5% dextrose injection is indicated for replacement of acute extracellular fluid volume losses in surgery, trauma, burns or shock. normosol-r and 5% dextrose also can be used as an adjunct to restore a decrease in circulatory volume in patients with moderate blood loss. the solution is not intended to supplant transfusion of whole blood or packed red cells in the presence of uncontrolled hemorrhage or severe reductions of red cell volume. none known.
normosol-m and dextrose- dextrose monohydrate, sodium chloride, potassium acetate, and magnesium acetate injection, solution
hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium acetate (unii: m911911u02) (potassium cation - unii:295o53k152), magnesium acetate (unii: 0e95jzy48k) (magnesium cation - unii:t6v3lhy838) - dextrose monohydrate 5 g in 100 ml - normosol-m and 5% dextrose injection (multiple electrolytes and 5% dextrose injection type 1, usp) is indicated for parenteral maintenance of routine daily fluid and electrolyte requirements with minimal carbohydrate calories from dextrose. magnesium in the formula may help to prevent iatrogenic magnesium deficiency in patients receiving prolonged parenteral therapy. none known.